Results 81 to 90 of about 12,622 (280)

Neurosteroids reduce social isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated upregulation of BDNF expression

open access: yesFrontiers in Endocrinology, 2011
The pharmacological action of SSRI antidepressants may include a normalization of the decreased brain levels of neurosteroids such as that of the progesterone metabolite allopregnanolone and that of the brain-derived neurotrophic factor (BDNF), which are
Mauricio Schüler Nin   +5 more
doaj   +1 more source

Site-specific effects of neurosteroids on GABAA receptor activation and desensitization

open access: yeseLife, 2020
This study examines how site-specific binding to three identified neurosteroid-binding sites in the α1β3 GABAA receptor (GABAAR) contributes to neurosteroid allosteric modulation. We found that the potentiating neurosteroid, allopregnanolone, but not its
Yusuke Sugasawa   +12 more
doaj   +1 more source

Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience [version 1; peer review: 4 approved]

open access: yesF1000Research, 2019
The GABAergic deficit hypothesis of depression states that a deficit of GABAergic transmission in defined neural circuits is causal for depression. Conversely, an enhancement of GABA transmission, including that triggered by selective serotonin reuptake ...
Bernhard Lüscher, Hanns Möhler
doaj   +1 more source

Pharmacological effect of one icv dose of Allopregnanolone in female rat: behavioural profile [PDF]

open access: yes, 2015
We have previously observed that intracerebroventricular allopregnanolone (ALLO) injection produced an anxiolytic effect and inhibited sexual receptivity when the test was performed in a separate manner. Also, ALLO reverts learning deficit in female rats
Cabrera Kreiker, Ricardo Jorge   +5 more
core  

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next?

open access: yesFrontiers in Endocrinology, 2020
Allopregnanolone, today best known as brexanolone and marketed as Zulresso for the treatment of postpartum depression is part of only two recently Food and Drug Administration (FDA)approved fast-acting antidepressants, with esketamine nasal spray, an ...
G. Pinna
semanticscholar   +1 more source

Allopregnanolone and neurogenesis in the nigrostriatal tract [PDF]

open access: yesFrontiers in Cellular Neuroscience, 2014
Reinstalling the neurobiological circuits to effectively change the debilitating course of neurodegenerative diseases is of utmost importance. This reinstallation requires generation of new cells which are able to differentiate into specific types of neurons and modification of the local environment suitable for integration of these new neurons into ...
openaire   +3 more sources

Why may allopregnanolone help alleviate loneliness? [PDF]

open access: yesMedical Hypotheses, 2015
Impaired biosynthesis of Allopregnanolone (ALLO), a brain endogenous neurosteroid, has been associated with numerous behavioral dysfunctions, which range from anxiety- and depressive-like behaviors to aggressive behavior and changes in responses to contextual fear conditioning in rodent models of emotional dysfunction.
S, Cacioppo, J T, Cacioppo
openaire   +2 more sources

Women with epilepsy: Evidence‐based counseling across the lifespan

open access: yesEpilepsia, EarlyView.
Abstract Women with epilepsy (WWE) encounter distinct and evolving challenges across the lifespan that require clinical management extending beyond seizure control alone. Although awareness of sex‐specific aspects of epilepsy has increased, important gaps remain in their integration into routine care.
Barbara Tettenborn   +7 more
wiley   +1 more source

Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis [PDF]

open access: yes, 2010
Benzodiazepines (BDZs) enhance GABA(A) receptor inhibition by direct actions on central BDZ receptors (CBRs). Although some BDZs also bind mitochondrial receptors [translocator protein (18 kDa) (TSPO)] and promote the synthesis of GABA-enhancing ...
Izumi, Yukitoshi   +3 more
core   +2 more sources

Home - About - Disclaimer - Privacy